Boehringer Japan Unit Plans 15 New Drugs Over Next Five Years
This article was originally published in PharmAsia News
Boehringer Ingelheim Japan said it has plans to bring 15 innovative drugs to the local market over the next five years, beginning with cancer and hepatitis C treatments.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.